Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 1/20 | 0.34 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25448139 | 0.86 | CTSC (0.34) | CTSCNOD1L3MBTL1KMT2APOLB | |
| SCHEMBL23446793 | 0.84 | L3MBTL1 (0.35) | CTSCNOD1L3MBTL1KMT2APOLB | |
| SCHEMBL24966603 | 0.84 | L3MBTL1 (0.35) | CTSCNOD1L3MBTL1KMT2APOLB | |
| SCHEMBL23380920 | 0.82 | FOLH1 (0.46) | CTSC | |
| SCHEMBL25454303 | 0.82 | ALDH1A1 (0.42) | — | |
| SCHEMBL22300762 | 0.81 | HDAC3 (0.32) | NOD1L3MBTL1KMT2APOLB | |
| SCHEMBL26535566 | 0.79 | L3MBTL1 (0.36) | CTSCNOD1L3MBTL1KMT2APOLB | |
| SCHEMBL23792690 | 0.78 | NOD1 (0.34) | CTSCNOD1L3MBTL1KMT2APOLB | |
| SCHEMBL20099412 | 0.78 | NOD1 (0.34) | NOD1KMT2APOLB | |
| SCHEMBL16021389 | 0.77 | FOLH1 (0.40) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | Shanghai MICURX Pharmaceuticals Co., Ltd. (CN) | 2023-05-11 | — | — | US | disclosed |
| WO-2021150792-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | MICURX PHARMACEUTICALS, INC. (US) | 2021-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | GLS, ATP6V1B1, KRAS | CTSC 1540/4885NOD1 4254/4885L3MBTL1 4698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.